Patel Naimish 4
4 · CRISPR Therapeutics AG · Filed Mar 18, 2025
Insider Transaction Report
Form 4
Patel Naimish
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-03-14+46,667→ 46,667 totalExercise: $42.12Exp: 2035-03-14→ Common Shares (46,667 underlying) - Award
Restricted Stock Units
2025-03-14+32,500→ 32,500 total→ Common Shares (32,500 underlying)
Footnotes (3)
- [F1]This option was granted on March 14, 2025 with respect to 46,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.